Cargando…

Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure

INTRODUCTION: Vulvodynia is a difficult condition to treat due to both the uncertain etiology of the disorder and poorly available therapies. This difficulty leads to a disproportionately high prevalence and cost of treatment for this condition. Candida vulvovaginitis is a frequent co-present diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothenberger, Rodger, Jones, Wendy, MacNeill, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360923/
https://www.ncbi.nlm.nih.gov/pubmed/34246854
http://dx.doi.org/10.1016/j.esxm.2021.100383
_version_ 1783737846742384640
author Rothenberger, Rodger
Jones, Wendy
MacNeill, Colin
author_facet Rothenberger, Rodger
Jones, Wendy
MacNeill, Colin
author_sort Rothenberger, Rodger
collection PubMed
description INTRODUCTION: Vulvodynia is a difficult condition to treat due to both the uncertain etiology of the disorder and poorly available therapies. This difficulty leads to a disproportionately high prevalence and cost of treatment for this condition. Candida vulvovaginitis is a frequent co-present diagnosis in vulvodynia patients. Whether through treatment of co-present, candida vulvovaginitis or by systemic interaction, itraconazole has been proposed as a treatment for vulvodynia. AIM: To describe objective change in vulvodynia pain in a cohort of patients treated with itraconazole. METHODS: This study was a retrospective cohort study comprised of women diagnosed with vulvodynia who were treated with itraconazole between January 1, 2011 and October 17, 2017. Patients had failed fluconazole treatment and had negative fungus cultures for >2 months before itraconazole treatment. All other vulvovaginal disorders were excluded. MAIN OUTCOME MEASURE: The main outcome measure was the change in pain before and after treatment as measured by cotton swab testing. RESULTS: 106 patients met inclusion criteria. Average pain reduction for the entire cohort was 60.7%. Patients who continued itraconazole for 5 to 8 weeks demonstrated a 69.6% reduction in cotton swab test pain. Pain reduction as a percentage of total patients showed complete resolution of pain in 37.7% of patients and >50% reduction in 66.0% of patients. Two-sample paired T-tests for means analysis of pain scores disproved the null hypothesis (P < .01, α = 0.01) and showed a 50% reduction in pain to be significant (P = 0.043, α = 0.05). Two-tailed Wilcoxon signed rank test also demonstrated rejection of the null hypothesis (α = 0.05). CONCLUSIONS: Itraconazole therapy is associated with a significant reduction in vulvovaginal pain in patients with negative fungus cultures and no other identifiable disease in this pilot study. A randomized placebo-controlled trial is warranted. Rothenberger R, Jones W, MacNeill C. Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure. J Sex Med 2021;9:100383
format Online
Article
Text
id pubmed-8360923
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83609232021-08-17 Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure Rothenberger, Rodger Jones, Wendy MacNeill, Colin Sex Med Original Research INTRODUCTION: Vulvodynia is a difficult condition to treat due to both the uncertain etiology of the disorder and poorly available therapies. This difficulty leads to a disproportionately high prevalence and cost of treatment for this condition. Candida vulvovaginitis is a frequent co-present diagnosis in vulvodynia patients. Whether through treatment of co-present, candida vulvovaginitis or by systemic interaction, itraconazole has been proposed as a treatment for vulvodynia. AIM: To describe objective change in vulvodynia pain in a cohort of patients treated with itraconazole. METHODS: This study was a retrospective cohort study comprised of women diagnosed with vulvodynia who were treated with itraconazole between January 1, 2011 and October 17, 2017. Patients had failed fluconazole treatment and had negative fungus cultures for >2 months before itraconazole treatment. All other vulvovaginal disorders were excluded. MAIN OUTCOME MEASURE: The main outcome measure was the change in pain before and after treatment as measured by cotton swab testing. RESULTS: 106 patients met inclusion criteria. Average pain reduction for the entire cohort was 60.7%. Patients who continued itraconazole for 5 to 8 weeks demonstrated a 69.6% reduction in cotton swab test pain. Pain reduction as a percentage of total patients showed complete resolution of pain in 37.7% of patients and >50% reduction in 66.0% of patients. Two-sample paired T-tests for means analysis of pain scores disproved the null hypothesis (P < .01, α = 0.01) and showed a 50% reduction in pain to be significant (P = 0.043, α = 0.05). Two-tailed Wilcoxon signed rank test also demonstrated rejection of the null hypothesis (α = 0.05). CONCLUSIONS: Itraconazole therapy is associated with a significant reduction in vulvovaginal pain in patients with negative fungus cultures and no other identifiable disease in this pilot study. A randomized placebo-controlled trial is warranted. Rothenberger R, Jones W, MacNeill C. Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure. J Sex Med 2021;9:100383 Elsevier 2021-07-09 /pmc/articles/PMC8360923/ /pubmed/34246854 http://dx.doi.org/10.1016/j.esxm.2021.100383 Text en Copyright © 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Rothenberger, Rodger
Jones, Wendy
MacNeill, Colin
Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure
title Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure
title_full Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure
title_fullStr Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure
title_full_unstemmed Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure
title_short Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure
title_sort itraconazole improves vulvodynia in fungus culture-negative patients post fluconazole failure
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360923/
https://www.ncbi.nlm.nih.gov/pubmed/34246854
http://dx.doi.org/10.1016/j.esxm.2021.100383
work_keys_str_mv AT rothenbergerrodger itraconazoleimprovesvulvodyniainfungusculturenegativepatientspostfluconazolefailure
AT joneswendy itraconazoleimprovesvulvodyniainfungusculturenegativepatientspostfluconazolefailure
AT macneillcolin itraconazoleimprovesvulvodyniainfungusculturenegativepatientspostfluconazolefailure